Radiotherapy for renal-cell carcinoma

De Meerleer, Gert; Khoo, Vincent; Escudier, Bernard; Joniau, Steven; Bossi, Alberto; Ost, Piet; Briganti, Alberto; Fonteyne, Valérie; Van Vulpen, Marco; Lumen, Nicolaas; Spahn, Martin; Mareel, Marc (2014). Radiotherapy for renal-cell carcinoma. The lancet oncology, 15(4), e170-e177. Elsevier 10.1016/S1470-2045(13)70569-2

Text Spahn_Lancet Oncol_Radiotherapy.pdf - Published Version Restricted to registered users only Available under License Publisher holds Copyright. Download (262kB)

Renal-cell carcinoma is considered to be a radioresistant tumour, but this notion might be wrong. If given in a few (even single) fractions, but at a high fraction dose, stereotactic body radiotherapy becomes increasingly important in the management of renal-cell carcinoma, both in primary settings and in treatment of oligometastatic disease. There is an established biological rationale for the radiosensitivity of renal-cell carcinoma to stereotactic body radiotherapy based on the ceramide pathway, which is activated only when a high dose per fraction is given. Apart from the direct effect of stereotactic body radiotherapy on renal-cell carcinoma, stereotactic body radiotherapy can also induce an abscopal effect. This effect, caused by immunological processes, might be enhanced when targeted drugs and stereotactic body radiotherapy are combined. Therefore, rigorous, prospective randomised trials involving a multidisciplinary scientific panel are needed urgently.

Interest & Impact

Downloads

1 since deposited on 26 Feb 2015
0 in the past 12 months

Citations

5 Citations in Web of Science ®
6 Citations in Scopus

Search

in Google Scholar™

Services

Actions (login required)

Edit item

Actions (login required)

Edit item